MedImmune, the global biologics research and development arm of AstraZeneca, is probably best known for its work in discovering and developing therapeutics based on antibodies -protein molecules produced by the body as a primary immune response. However, for a number of reasons, including the large size of the molecule, antibodies may not always offer the most appropriate solution for treating some diseases. In those cases there may be alternative, innovative approaches which can be explored in parallel with our usual work with antibodies.
{iframe}http://www.cambridge-news.co.uk/8203-Nanoscience-takes-MedImmune-different/story-25935552-detail/story.html{/iframe}